Want to cut your energy bills? Here’s how five experts are doing it 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
NEW YORK, March 24, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Horizon Pharma plc (“Horizon” or the “Company”) (Nasdaq:HZNP) between March 13, 2014 and February 26, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Horizon securities between March 13, 2014 and February 26, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/horizon-pharma.
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Horizon’s Prescriptions Made Easy (“PME”) program was designed to artificially inflate the prices of minor differentiation standard retail drugs; (ii) sales revenues from drugs sold through Horizon’s PME program were unsustainable at these inflated price levels; and (iii) Horizon’s use of its PME program left the Company subject to increased regulatory risks.
On February 29, 2016, Horizon disclosed in its 2015 annual report that the Company received a subpoena in November 2015 from the Office of the U.S. Attorney for the Southern District of New York for documents and information related to the Company’s patient assistance programs and other aspects of Horizon’s sales and marketing activities.
If you suffered a loss in Horizon you have until May 9, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/horizon-pharma.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
